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Dietary acrylamide intake and the risk of renal cell, bladder, and
prostate cancer1–3
Janneke G Hogervorst, Leo J Schouten, Erik J Konings, R Alexandra Goldbohm, and Piet A van den Brandt
ABSTRACT
Background: Acrylamide, a probable human carcinogen, was re-
cently detected in various heat-treated carbohydrate-rich foods. Ep-
idemiologic studies on the relation with cancer have been few and
largely negative.
Objective: We aimed to prospectively examine the association be-
tween dietary acrylamide intake and renal cell, bladder, and prostate
cancers.
Design: The Netherlands Cohort Study on diet and cancer includes
120 852 men and women aged 55–69 y. At baseline (1986), a ran-
dom subcohort of 5000 participants was selected for a case-cohort
analysis approach using Cox proportional hazards analysis. Acryl-
amide intake was assessed with a food-frequency questionnaire at
baseline and was based on chemical analysis of all relevant Dutch
foods.
Results: After 13.3 y of follow-up, 339, 1210, and 2246 cases of
renal cell, bladder, and prostate cancer, respectively, were available
for analysis. Compared with the lowest quintile of acrylamide intake
(mean intake: 9.5 g/d), multivariable-adjusted hazard rates for
renal cell, bladder, and prostate cancer in the highest quintile (mean
intake: 40.8g/d) were 1.59 (95% CI: 1.09, 2.30; P for trend0.04),
0.91 (95% CI: 0.73, 1.15; P for trend  0.60), and 1.06 (95% CI:
0.87, 1.30; P for trend  0.69), respectively. There was an inverse
nonsignificant trend for advanced prostate cancer in never smokers.
Conclusions: We found some indications for a positive association
between dietary acrylamide and renal cell cancer risk. There were no
positive associations with bladder and prostate cancer risk. Am
J Clin Nutr 2008;87:1428–38.
INTRODUCTION
Acrylamide (C3H5NO) is a small hydrophilic molecule that
polymerizes readily in the presence of an initiator because of the
double bond between the first and second C-atoms, which makes
it a versatile industrial chemical. In 1994, the International
Agency for Research on Cancer classified acrylamide as a prob-
able human carcinogen, on the basis of its carcinogenicity in
rodents (1). Before 2002, acrylamide exposure was thought to
occur mainly through occupational exposure, also through cig-
arette smoke, and to a minor extent through the consumption of
water and the use of cosmetics. However, in 2002, Swedish
scientists reported its presence in carbohydrate-rich foods that
were produced at high temperatures, such as French fries and
potato chips (2). This finding alarmed the scientific community,
particularly because acrylamide is present in foods at consider-
ably higher concentrations than are other well-known food car-
cinogens, such as polycyclic aromatic hydrocarbons and ethyl
carbamate (3). Shortly after its discovery in food, acrylamide was
shown to form in Maillard browning reactions, in which amino
acids, particularly asparagine, react with reducing sugars at high
temperatures (120 °C) (4, 5).
The mechanism by which acrylamide causes cancer in labo-
ratory animals and by which it may cause cancer in humans is as
yet unclear (6); both genotoxic and nongenotoxic pathways have
been suggested. Acrylamide itself and its epoxide metabolite
glycidamide, which is generated by cytochrome P4502E1
(CYP2E1), are clastogenic, and glycidamide forms DNA ad-
ducts. As for possible nongenotoxic pathways, acrylamide reacts
with glutathione and may thus influence the redox status of cells
and gene transcription, or it may interfere with DNA repair or
hormonal balances (6).
Animal studies have shown positive dose-response relations
between acrylamide exposure and cancer in multiple organs in
both mice and rats (7–10); included among those organs were
several hormone-sensitive organs, such as the mammary glands
and the uterus. Studies of occupational acrylamide exposure
have been negative so far, apart from a finding of a greater risk of
pancreatic cancer, but that finding was based on a small number
of cases (11–16). Dietary acrylamide intake and its relation with
various types of cancer have been studied in few case-control
studies (17–19) and only 2 prospective cohort studies (20, 21).
One prospective cohort study by our group showed a positive
association between dietary acrylamide intake and risks of en-
dometrial and ovarian cancers but not postmenopausal breast
cancer (22).
Because the acrylamide molecule is small and hydrophilic, it
passively diffuses throughout the body (23). For this reason, all
tissues are theoretically targets for acrylamide carcinogenesis. In
the present prospective cohort study, we investigated the relation
between dietary acrylamide and risk of cancer of the kidney,
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bladder, and prostate. Prostate cancer was of particular interest
because of its hormonal etiology.
SUBJECTS AND METHODS
Study cohort, cases, and follow-up
The Netherlands Cohort Study on diet and cancer (NLCS)
began in September 1986 with the enrollment of 58 279 men and
62 573 women aged 55–69 y. At baseline, the participants com-
pleted a self-administered questionnaire on 150 food items and
on possible risk factors for cancer, such as smoking, occupation,
and physical activity.
Participants were informed that, by returning a completed
questionnaire, they gave their consent to participate in a study of
the etiology of cancer in relation to diet. The study protocol was
approved by the Medical Ethics Committees of the University
Hospital Maastricht and TNO Nutrition.
Data processing and analysis were based on the case-cohort
approach, in which the cases were enumerated for the entire
cohort (providing the numerator information for estimating in-
cidence rates), whereas the accumulated person-years for the
entire cohort were estimated from a subcohort of 5000 men and
women randomly sampled from the entire cohort at baseline
(providing the denominator information for estimating incidence
rates). Thus, all of the incident cases in the total cohort were used
in the analyses. The size of the subcohort was based on calcula-
tions that were described previously (24). Since the start of the
study, vital status information was obtained from the subcohort
at regular intervals. Incident cases in the total cohort have been
detected by annual computerized record linkages to the regional
cancer registries and the Netherlands Pathology Registry. The
completeness of cancer follow-up through linkage with the can-
cer registries was estimated to be96% (25). The follow-up of
the subcohort was nearly 100% complete (only 2 male subcohort
members were lost to follow-up) at the end of the follow-up
period. Further details on the design of the study and methods of
follow-up were presented elsewhere (24, 26–28).
The analyses are based on 13.3 y of follow-up, from Septem-
ber 1986 through December 1999. After the 13.3-y follow-up,
there were 402, 1381, and 2599 incident, epithelial, microscop-
ically confirmed cases of primary renal cell [International Clas-
sification of Diseases for Oncology (ICD-O)-3: C64], bladder
(ICD-O-3: C67), and prostate (ICD-O-3: C61) carcinoma, re-
spectively. There were 759 invasive bladder cancer cases and
734 papillary, noninvasive bladder cancer cases. Some bladder
cancer cases had both an invasive and a papillary noninvasive
tumor. As for prostate cancer, 947 cases, defined by tumor (T)
and metastasis (M) status, were of the advanced prostate cancer
type [which entails stage III prostate cancer (T3–4, M0) and
stage IV prostate cancer (T0–4, M1); American Joint Committee
on Cancer classification], and 1546 were of the localized type
(T0–2, M0), whereas 106 cases had tumors of unknown stage.
Cases and subcohort members were excluded from analysis if
they had been diagnosed with cancer (other than nonmelanoma
skin cancer) at baseline and if their dietary data were incomplete
or inconsistent. The selection and exclusion steps that resulted in
the numbers of cases and subcohort members that were available
for analysis are shown in Figure 1.
Acrylamide intake assessment
The NLCS food-frequency questionnaire (FFQ) contained
questions on 150 food items (27). The acrylamide intake was
estimated from the mean acrylamide concentration of food items
and the frequency of consumption and portion size of the food
items.
To obtain an intake estimate representative of the Dutch diet,
we used data on acrylamide concentrations in food products on
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FIGURE 1. Flow diagram of subcohort members and cases on whom the analyses were based. NCR, the Netherlands Cancer Registry; PALGA, the
Netherlands Pathology Registry; RCC, renal cell cancer; BC, bladder cancer; PC, prostate cancer.
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the Dutch market. In 2002, the Dutch Food and Consumer Prod-
uct Safety Authority used an elaborate sampling scheme to an-
alyze acrylamide concentrations in various foods, such as bread,
French fries, pastry and cake, Dutch spiced cake, potato chips,
cornflakes, meat, fish, and several beverages (29). In 2005, more
foods were analyzed to specifically accommodate the estimation
of the acrylamide intake of the NLCS cohort; this series consisted
of bread, rusk, specific types of cookies, rye bread, crisp bread,
pastry and cake, chocolate and chocolate milk, nuts and salty
snacks, peanut butter, and coffee (30). Bread was sampled and
analyzed again in 2005, because the quantitation limit of the
analytic method had decreased from 30 ppb in 2002 to 15 ppb in
2005, and that change offered the opportunity to more accurately
estimate the acrylamide content of bread.
The foods that were used in the acrylamide intake assessment
were assigned the mean value of the acrylamide values per food
or a value one-half the quantitation limit when concentrations
were lower than the quantitation limit (because even those foods
probably do contain some acrylamide). Other foods (ie, meats,
cooked and raw vegetables, and dairy products) were assigned
the value zero. Because acrylamide concentrations in individual
foods vary considerably, our group has performed a validation
study to investigate whether using mean acrylamide concentra-
tions in foods results in a sound estimate of total acrylamide
intake (data not shown). The acrylamide content of 39 duplicate
24-h Dutch meals from 2004 was estimated by using the menu list
(on which amounts of individual foods in the 24-h meals were
listed) that the participants of the duplicate meal study filled in for
their duplicate meals, and the same mean acrylamide concentra-
tions for foods that were used in the NLCS study. Next, the
acrylamide concentrations of the duplicate meals were chemi-
cally analyzed and correlated to the estimated acrylamide con-
tent, which rendered a Spearman correlation coefficient of 0.78.
This finding indicates that it is feasible to make a sound rank
ordering of the acrylamide intake via a 24-h meal by using these
mean acrylamide concentrations for individual foods. The acryl-
amide concentrations of foods that were used in the acrylamide
intake assessment are shown in Table 1.
Statistical analysis
Acrylamide was included in the statistical models as a contin-
uous variable and as a quintile distribution. Furthermore, the fifth
quintile was split into 2 deciles to investigate the highest 10% of
the intake, which is more in line with the intake of current pop-
ulations in developed countries (31), such as the Netherlands.
A priori, on the basis of the literature, variables, besides age
and sex, were selected for inclusion in the multivariable-adjusted
models. For renal cell cancer, those variables were hypertension,
body mass index, energy intake, fruit consumption, and vegeta-
ble consumption; for bladder cancer, they were vegetable con-
sumption, fruit consumption, tea consumption, and family his-
tory of bladder cancer; and for prostate cancer, they were
socioeconomic status (SES), alcohol intake, and family history
of prostate cancer (32). Other variables were included in the
models if they changed the age- and sex-adjusted hazard ratios
(HRs) of acrylamide (expressed as the interval between the 10th
and 90th percentiles of intake: 27 g acrylamide/d) by 10%.
Different groups of variables were checked for confounding po-
tential on the basis of this change of estimate rule. For renal cell
cancer analysis, those variables were SES, physical activity, tea
consumption, and a family history of renal cell cancer; for blad-
der cancer analysis, they were body mass index, SES, total fluid
intake, energy intake, and meat, fish, and cheese intakes; and for
prostate cancer analyses, they were body mass index, height,
physical activity, energy intake, and meat, fish, vegetable, fruit,
and dairy consumption. We also checked the following broad
categories of foods or nutrients for confounding potential for the
3 cancer types: alcohol consumption, energy-adjusted intake of
saturated fat, trans unsaturated fatty acids, carbohydrates, and
dietary fiber. Because cigarette smoke is a very important source
of acrylamide, smoking status (current or not current), the dura-
tion of smoking, and the number of cigarettes per day were
included in the model for the total group (but not in the analyses
for never smokers). Smokers have been shown to have, on av-
erage, 4 times the concentrations of acrylamide-hemoglobin ad-
ducts in their blood—a marker of the internal dose of acryl-
amide—as do nonsmokers (33, 34). For that same reason,
subgroup analyses were performed for never smokers.
The proportional hazards assumption was tested by using
scaled Schoenfeld residuals. HRs (and 95% CIs) were obtained
by using Cox proportional hazards regression and STATA soft-
ware (version 9.2; Stata Corp, College Station, TX). SEs were
estimated by using the robust Huber-White sandwich estimator
to account for additional variance introduced by sampling from
the cohort. Tests for dose-response trends were performed by
fitting the median acrylamide intake in each quintile for the
TABLE 1
Acrylamide concentrations in foods used for the NLCS acrylamide intake
assessment1
Samples Mean Minimum Maximum
n g/kg g/kg g/kg
Potato chips 40 1249 310 2800
Dutch spiced cake 13 1018 260 1410
French fries 33 351 LOQ2 1220
Salty snacks 12 277 45 867
Crisp bread 12 229 15 914
Cookies3 20 204 10 829
Cornflakes 12 121 LOQ2 300
Peanut butter 2 113 107 118
Chocolate 6 60 22 116
Nuts 8 33 LOQ4 83
Rusk 3 25 16 33
Rye bread 13 24 LOQ5 60
Sweet pastry 19 18 LOQ4 111
Coffee6 9 17 9 28
Chocolate milk 4 LOQ4 LOQ4 LOQ4
Bread 22 LOQ4 LOQ4 LOQ4
1 NLCS, Netherlands Cohort Study; LOQ, limit of quantitation.
2 LOQ in 2002 was 60 g/kg.
3 Measurements in cookies were performed in several types of cookies
known to be eaten most frequently by the population comparable to that of the
NLCS, according to information from the development phase of the ques-
tionnaire. Thus, an acrylamide concentration in cookies was based on the
acrylamide concentration in the specific types of cookies weighted by the
frequency of consumption by the NLCS-comparable population. The same
was done for other composite food items, such as bread.
4 LOQ in 2005 was 15 g/kg.
5 LOQ in 2002 was 30 g/kg.
6 Analyzed in brewed filtered coffee that was prepared according to
general Dutch preparation instructions (7 g coffee powder/125 mL water).
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quintiles of acrylamide intake. To investigate whether the ob-
served associations could be attributed to acrylamide itself or
whether the association was due to other characteristics of
acrylamide-containing foods than the acrylamide content, mod-
els were run with acrylamide and the foods (one at a time) that
explained most variance in acrylamide intake.
Effect modification of the association between acrylamide
intake and cancer by other variables was tested by using Wald
chi-square tests. The variables that were tested for effect modi-
fication were selected on the basis of their ability to modify the
activity of CYP2E1, the enzyme that converts acrylamide to
glycidamide. Other acrylamide researchers have recommended
studying the interaction between dietary acrylamide intake and
factors that influence the expression of this enzyme in epidemi-
ologic studies (35, 36). These variables are diabetes, obesity,
smoking, alcohol consumption, and physical activity (35, 37–
39). The categories of these variables were a priori based either
on existing categories in the NLCS database (physical activity) or
on the number of subcohort members within the categories, to
strive for sufficient participants in each category (number of
cigarettes smoked/d, number of smoking years, and alcohol in-
take). Throughout, 2-sided P values are reported.
RESULTS
On average, the subcohort members had a mean (SD) daily
acrylamide intake of 21.8  12.0 g/d, which corresponds to
0.30  0.18 g acrylamide  kg body wt1  d1. Men had a
slightly higher absolute intake (22.5 12.1 g/d) but a slightly
lower intake per kg body wt (0.29  0.16 g  kg body
wt1  d1 than did women (absolute: 21.0 11.9 g/d; per kg
body wt: 0.32 0.19g  kg body wt1  d1). Although coffee
was overall the most important contributor to acrylamide intake,
Figure 2 shows that it was not coffee but, rather, Dutch spiced
cake that was chiefly responsible for the variations in acrylamide
intake in the population of the present study; next most respon-
sible were coffee, French fries, potato chips, and cookies. These
findings applied to both men and women.
The values of the covariables that were assessed for confound-
ing potential for the subcohort and for the cases, separately for
men and women, are shown in Table 2. There were no striking
differences between cases and subcohort members for most of
the variables. Only smoking (current smoking, number of ciga-
rettes per day, and number of smoking years) was more prevalent
among bladder cancer cases and among male renal cell cancer
cases than among subcohort members.
The age- and multivariable-adjusted associations between
acrylamide intake and renal cell cancer risk for men and women
combined are shown in Table 3. There was a statistically sig-
nificant positive association between acrylamide as a continuous
variable and renal cell cancer risk in the group of men and women
combined (HR: 1.10; 95% CI: 1.01, 1.21) per each 10-g incre-
ment in acrylamide/d. For men and women separately, the HRs
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FIGURE 2. Relative and absolute contributions of foods to the mean daily dietary acrylamide intake of the present subcohort of the Netherlands Cohort
Study. Left panels, men; right panels, women.
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were similar, 1.10 (0.98, 1.23) and 1.11 (0.94, 1.31), respec-
tively. In the group of men and women combined, there was a
significant (P  0.04) positive trend from the lowest to the
highest quintile of acrylamide intake, with an HR of 1.59 (1.09,
2.30) in the highest quintile compared with the lowest. This
pattern was observed in both men and women. There was no
association in the subgroup of never smokers.
The associations between acrylamide intake and bladder
cancer risk for men and women combined are presented in
Table 4. Acrylamide intake was not associated with bladder
cancer risk when male and female never, former, and current
smokers were combined. Moreover, in the subgroup of par-
ticipants within the highest decile of acrylamide intake, no
greater risk was observed. However, in the never-smoking
subgroup, acrylamide intake tended to be inversely associated
with bladder cancer risk (P for trend 0.07), but there was no
linear dose-response relation. Stratification of the analyses by
sex showed that an inverse association was found in women
TABLE 2
Characteristics of cases and subcohort members in the Netherlands Cohort Study on diet and cancer (NLCS), 1986–1999
Variable
Men Women
Subcohort1
(n 2191)3
Renal cell
cancer
cases
(n 241)
Bladder
cancer
cases
(n 1100)
Prostate
cancer
cases
(n 2432)
Subcohort2
(n 2247)
Renal cell
cancer
cases
(n 135)
Bladder
cancer
cases
(n 190)
Dietary variables
Acrylamide intake (g/d) 22.6 12.24 23.0 11.8 23.0 11.9 22.4 11.7 21.0 11.9 22.2 13.8 19.9 13.5
Acrylamide intake (g  kg BW1  d1) 0.29 0.16 0.30 0.16 0.30 0.16 0.29 0.16 0.32 0.19 0.32 0.20 0.30 0.21
Coffee (g/d) 578 290 609 264 620 308 559 260 497 245 526 253 484 258
Dutch spiced cake (g/d) 4.1 8.6 4.4 8.9 4.2 8.8 4.7 9.0 5.7 9.4 5.6 10.5 5.1 10.3
Cookies (g/d) 13.5 10.6 13.1 9.8 12.7 12.0 14.1 11.1 13.7 11.0 15.1 9.9 11.8 13.6
Potato chips (g/d) 0.47 1.72 0.52 2.10 0.42 1.67 0.43 1.80 0.40 1.93 0.45 1.79 0.34 1.33
French fries (g/d) 7.2 15.4 6.2 11.4 7.2 13.3 5.9 11.6 4.0 8.7 5.0 10.2 4.4 10.4
Total energy intake (kcal) 2166 511 2122 479 2174 484 2140 490 1686 398 1651 388 1631 381
Carbohydrate (g/d) 227 66 223 61 221 60 222 61 179 48 177 49 171 50
Saturated fat (g/d) 36.9 12.0 35.2 10.7 37.3 12.1 36.6 12.0 29.8 9.8 29.1 9.5 29.3 9.4
trans Unsaturated fatty acid (g/d) 3.3 1.7 3.1 1.6 3.3 1.6 3.2 1.6 2.5 1.2 2.5 1.2 2.4 1.1
Fiber (g/d) 28.7 8.7 29.1 9.1 28.3 7.9 28.7 8.2 25.3 7.0 25.2 6.9 25.1 7.4
Vegetables (g/d) 192 85 198 88 191 80 192 80 196 81 186 67 189 80
Fruit (g/d) 154 114 153 114 150 119 160 110 196 121 183 109 194 128
Dairy products (g/d) 309 218 304 214 299 212 308 200 299 188 273 178 285 186
Meat (g/d) 106 43 103 45 110 48 103 42 93 40 94 39 93 44
Fish (g/d) 14.2 16.7 17.0 19.6 14.7 16.0 14.2 16.4 11.7 13.8 12.2 15.1 11.3 10.6
Alcohol (g/d) 15.0 16.8 13.9 15.1 17.5 17.5 15.0 16.4 5.9 9.5 4.9 8.7 6.7 11.4
Tea (cups/d)5 2.5 2.0 2.3 1.9 2.4 2.0 2.7 2.0 3.0 2.1 3.2 2.3 3.0 2.1
Nondietary variables
Age (y) 61.3 4.2 61.8 3.8 62.3 4.0 62.6 4.0 61.4 4.3 61.8 4.0 62.1 4.3
BMI (kg/m2) 25.0 2.6 25.3 2.6 24.9 2.5 25.0 2.5 25.1 3.6 25.8 3.5 25.1 3.6
Height (cm) 176 7 177 7 177 7 176 7 165 6 166 6 164 6
Nonoccupational physical activity (min/d) 80 68 78 62 78 65 78 61 64 53 62 47 67 62
Cigarettes (n/d) 14.7 11.4 17.2 12.9 16.9 11.1 14.1 11.6 4.6 7.7 4.6 8.0 7.2 9.4
Smoking (y) 29.4 15.8 31.9 15.2 34.9 14.0 28.9 16.5 11.4 15.8 11.0 15.4 17.6 18.4
Cigarette smoking
Never smokers (%) 12.7 8.7 6.4 14.4 58.4 57.8 44.7
Former smokers (%) 51.6 50.2 46.5 53.2 20.6 20.0 23.2
Current smokers (%) 35.7 41.1 47.2 32.4 21.0 21.5 32.1
Education
Primary school (%) 24.9 26.1 25.2 25.0 33.3 32.6 31.0
Lower vocational school (%) 20.6 22.8 19.9 17.6 23.1 25.2 17.0
Intermediate vocational or high school (%) 35.4 31.1 34.7 36.1 34.3 34.1 43.5
Higher vocational school or college (%) 18.6 19.5 19.4 20.6 8.8 7.4 8.5
Family history of renal cell cancer (%) 0.6 1.7 0.5 0.7 1.3 1.5 0.5
Family history of prostate cancer (%) 2.4 0.8 1.9 3.5 2.0 2.2 2.5
Family history of bladder cancer (%) 0.7 2.9 0.5 0.8 1.3 0.7 3.0
1 Male subcohort contained 8 renal cell cancer cases, 40 bladder cancer cases, and 107 prostate cancer cases.
2 Female subcohort contained 6 renal cell cancer cases and 7 bladder cancer cases.
3 The number of subcohort members or cases after exclusion of participants with prevalent cancer at baseline, with incomplete or inconsistent dietary data,
or both. The number of missing values varies for the variables in the table.
4 x  SD (all such values).
5 1 cup 125 mL.
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(although it was not statistically significant and did not have
a linear dose-response relation), whereas, in men, the HRs
were 1. The same pattern was found in never-smoking
women. Similar results were observed for invasive bladder
cancer.
From the data given in Table 5, it can be concluded that there
were no indications of a positive association between acrylamide
intake and total prostate cancer risk. There also was no greater
HR in the highest decile of acrylamide intake. This finding was
similar for advanced prostate cancer. However, there was an
inverse statistically nonsignificant (P for trend  0.10) dose-
response relation between acrylamide intake and advanced pros-
tate cancer risk in never smokers.
Adjustment for coffee intake slightly decreased the HRs of the
highest quintiles of acrylamide intake and the continuous acryl-
amide variable for renal cell cancer. Adjustment for the other
foods did not change the HRs (data not shown).
The results of the analyses (men and women combined) of
interactions between acrylamide and possible CYP2E1-
influencing variables are shown In Table 6, Table 7, and Table
TABLE 3
Association between dietary acrylamide intake and renal cell cancer risk; the Netherlands Cohort Study on diet and cancer (NLCS), 1986–19991
Overall Never smokers
Cases Person-years HR (95% CI)2 HR (95% CI)3 Cases Person-years HR (95% CI)2 HR (95% CI)4
n n n n
Acrylamide intake (10 g/d) 339 49 600 1.07 (0.98, 1.16) 1.10 (1.01, 1.21) 93 19 202 1.08 (0.88, 1.31) 1.09 (0.89, 1.34)
Q1 56 9840 Ref (1.00) Ref (1.00) 15 4189 Ref (1.00) Ref (1.00)
Q2 66 9879 1.20 (0.83, 1.74) 1.25 (0.86, 1.83) 24 3930 1.73 (0.89, 3.36) 1.71 (0.87, 3.38)
Q3 76 9822 1.41 (0.98, 2.02) 1.48 (1.02, 2.15) 19 3384 1.67 (0.83, 3.34) 1.63 (0.80, 3.34)
Q4 62 10 077 1.14 (0.78, 1.66) 1.23 (0.83, 1.81) 15 3852 1.14 (0.54, 2.37) 1.15 (0.53, 2.49)
Q5 79 9981 1.43 (1.00, 2.04) 1.59 (1.09, 2.30) 20 3848 1.47 (0.74, 2.93) 1.51 (0.73, 3.10)
P for trend 0.12 0.04 0.73 0.68
1 HR, hazard ratio; Q, quintile. The numbers of cases and person-years are the numbers that resulted after listwise deletion of observations with missing
values for the selected confounders. HRs were calculated by using Cox proportional hazards analysis. The sex  acrylamide intake interaction was not
significant.
2 Adjusted for age and sex.
3 Adjusted for age, sex, hypertension (yes or no), BMI, energy intake, fruit consumption, vegetable consumption, smoking status (current or not current),
number of cigarettes per day, and number of years of smoking.
4 Adjusted for age, sex, hypertension (yes or no), BMI, energy intake, fruit consumption, and vegetable consumption.
TABLE 4
Association between dietary acrylamide intake and bladder cancer risk; the Netherlands Cohort Study on diet and cancer (NLCS), 1986–19991
Overall Never smokers
Cases Person-years HR (95% CI)2 HR (95% CI)3 Cases Person-years HR (95% CI)2 HR (95% CI)4
n n n n
Total bladder cancer
Acrylamide intake (10 g/d) 1210 51 111 1.01 (0.96, 1.07) 1.00 (0.95, 1.06) 155 19 903 0.90 (0.77, 1.06) 0.90 (0.76, 1.05)
Q1 249 10 108 Ref (1.00) Ref (1.00) 52 4363 Ref (1.00) Ref (1.00)
Q2 242 10 137 1.02 (0.82, 1.27) 0.96 (0.77, 1.20) 26 4060 0.58 (0.35, 0.98) 0.58 (0.34, 0.97)
Q3 229 10 121 1.00 (0.80, 1.24) 0.89 (0.71, 1.12) 24 3491 0.72 (0.42, 1.22) 0.73 (0.43, 1.25)
Q4 255 10 386 1.12 (0.90, 1.39) 1.01 (0.81, 1.26) 27 3989 0.69 (0.41, 1.15) 0.68 (0.40, 1.13)
Q5 235 10 360 0.97 (0.78, 1.21) 0.91 (0.73, 1.15) 26 4000 0.57 (0.34, 0.95) 0.55 (0.33, 0.93)
P for trend 0.93 0.60 0.08 0.07
Invasive bladder cancer
Acrylamide intake (10 g/d) 651 51 215 1.04 (0.97, 1.11) 1.03 (0.95, 1.11) 85 19 909 0.88 (0.70, 1.12) 0.88 (0.70, 1.12)
Q1 142 10 159 Ref (1.00) Ref (1.00) 34 4363 Ref (1.00) Ref (1.00)
Q2 127 10 158 0.95 (0.72, 1.25) 0.90 (0.68, 1.18) 16 4060 0.56 (0.30, 1.05) 0.56 (0.30, 1.06)
Q3 117 10 132 0.92 (0.69, 1.21) 0.81 (0.61, 1.08) 9 3491 0.43 (0.20, 0.91) 0.43 (0.20, 0.91)
Q4 122 10 404 0.96 (0.73, 1.26) 0.85 (0.64, 1.13) 10 3995 0.40 (0.19, 0.83) 0.40 (0.19, 0.83)
Q5 143 10 362 1.06 (0.81, 1.38) 1.00 (0.76, 1.31) 16 4000 0.54 (0.29, 1.01) 0.54 (0.28, 1.01)
P for trend 0.53 0.80 0.09 0.09
1 HR, hazard ratio; Q, quintile. The numbers of cases and person-years are the numbers that resulted after listwise deletion of observations with missing
values for the selected confounders. HRs were calculated through Cox proportional hazards analysis. The sex  acrylamide intake interaction was not
significant.
2 Adjusted for age and sex.
3 Adjusted for age, sex, vegetable consumption, fruit consumption, tea consumption, bladder cancer in the family, smoking status (current or not current),
number of cigarettes per day and number of years of smoking.
4 Adjusted for age, sex, vegetable consumption, fruit consumption, tea consumption, and bladder cancer in the family.
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8. For renal cell cancer (Table 6), there were no significant P
values for interaction for any of the possible CYP2E1-
influencing variables. In the bladder cancer analyses (Table 7),
cigarette smoking (ie, the number of cigarettes smoked/d)
significantly modified the association between acrylamide
and bladder cancer risk (P for interaction  0.02), and there
was a borderline statistically significant HR of 1.09 (1.00,
1.19) for persons smoking 15 cigarettes/d. Obese women
had a lower acrylamide-associated risk of bladder cancer (HR:
0.47; 95% CI: 0.21, 1.05; P for interaction  0.03) than did
nonobese women, although this finding was based on only 16
obese cases (data not shown). The P values for interaction
suggest that none of the variables statistically significantly
modified the prostate cancer risk associated with acrylamide
intake (Table 8).
DISCUSSION
This prospective cohort study provides indications that dietary
acrylamide intake may increase the risk of renal cell cancer. In 2
case-control studies in Sweden, no association between acryl-
amide intake and renal cell cancer risk was observed (18, 19), but
case-control studies may suffer from recall bias and selection
bias, which may distort true associations. These types of biases
are not relevant in the present prospective cohort study, which
includes a nearly complete follow-up. In never or former smok-
ers, there was no association between acrylamide and renal cell
cancer risk, which may be explained by the higher risk in the
subgroup with the longest duration of smoking (see Table 6).
Thus, there may be a synergy between acrylamide intake and
duration of smoking.
In the present study, acrylamide intake, overall, was not pos-
itively associated with a risk of bladder cancer, whether total or
invasive. This finding is in line with the only study on this topic
from Sweden. However, in that case-control study, the associa-
tion was not evaluated separately for men and women. In the
present study, there was a borderline statistically significant in-
verse trend but no clear linear dose-response relation for the
association between acrylamide intake and bladder cancer risk in
never smokers; this trend appeared to be restricted to the female
subgroup. On the basis of the present study alone, we do not make
a statement about whether there may be an inverse nonlinear
dose-response relation between acrylamide intake and bladder
cancer risk in women. It is too early to say whether the observed
significantly decreased HRs in some quintiles of acrylamide
intake represent a real biological effect or whether they are due
to random fluctuations. More research on acrylamide intake and
bladder cancer risk in women is needed. In contrast, there was a
significant positive interaction between acrylamide intake and
smoking in terms of the number of cigarettes smoked per day.
We found no positive association between acrylamide intake
and prostate cancer risk. We did, however, observe an inverse
linear trend in never smokers, but it was not statistically signif-
icant. In the only other epidemiologic study on dietary acryl-
amide intake and prostate cancer risk so far, no association was
observed (17), but, in that case-control study, no subgroup anal-
yses were performed for never smokers.
The relative risks of renal cell cancer associated with dietary
acrylamide intake that we have observed in the present study are
considerably higher than the relative risks that would be expected
on the basis of linear extrapolation of the results of a cancer
incidence study in rodents (40) that used the tissue that was most
TABLE 5
Association between dietary acrylamide intake and prostate cancer risk; the Netherlands Cohort Study on diet and cancer (NLCS), 1986–19991
Overall Never smokers
Cases Person-years HR (95% CI)2 HR (95% CI)3 Cases Person-years HR (95% CI)2 HR (95% CI)4
n n n n
Total prostate cancer
Acrylamide intake (10 g/d) 2246 23 208 1.01 (0.96, 1.06) 1.01 (0.96, 1.07) 347 3352 0.95 (0.83, 1.08) 0.95 (0.83, 1.09)
Q1 470 4631 Ref (1.00) Ref (1.00) 101 784 Ref (1.00) Ref (1.00)
Q2 473 4476 1.07 (0.88, 1.31) 1.07 (0.87, 1.31) 75 676 0.90 (0.56, 1.46) 0.84 (0.51, 1.38)
Q3 426 4761 1.00 (0.82, 1.23) 1.01 (0.82, 1.24) 53 553 0.88 (0.52, 1.50) 0.87 (0.50, 1.51)
Q4 406 4572 1.01 (0.82, 1.24) 1.02 (0.83, 1.26) 50 625 0.72 (0.42, 1.21) 0.73 (0.43, 1.24)
Q5 471 4769 1.05 (0.86, 1.29) 1.06 (0.87, 1.30) 68 715 0.75 (0.46, 1.22) 0.72 (0.43, 1.20)
P for trend 0.77 0.69 0.19 0.19
Advanced prostate cancer
Acrylamide intake (10 g/d) 741 23 208 1.02 (0.95, 1.09) 1.02 (0.95, 1.10) 117 3352 0.91 (0.75, 1.10) 0.90 (0.73, 1.11)
Q1 153 4631 Ref (1.00) Ref (1.00) 34 784 Ref (1.00) Ref (1.00)
Q2 166 4476 1.15 (0.88, 1.51) 1.15 (0.88, 1.51) 29 676 1.04 (0.55, 1.95) 0.98 (0.51, 1.88)
Q3 132 4761 0.95 (0.72, 1.26) 0.95 (0.71, 1.26) 17 553 0.86 (0.41, 1.78) 0.79 (0.38, 1.67)
Q4 133 4572 1.02 (0.77, 1.35) 1.02 (0.77, 1.36) 18 625 0.79 (0.39, 1.60) 0.76 (0.40, 1.57)
Q5 157 4769 1.08 (0.82, 1.41) 1.08 (0.82, 1.41) 19 715 0.63 (0.32, 1.23) 0.57 (0.27, 1.17)
P for trend 0.83 0.81 0.12 0.10
1 HR, hazard ratio; Q, quintile. The numbers of cases and person-years are the numbers that resulted after listwise deletion of observations with missing
values for the selected confounders. HRs were calculated through Cox proportional hazards analysis.
2 Adjusted for age.
3 Adjusted for age, socioeconomic status, prostate cancer in the family, alcohol intake, smoking status (current or not current), number of cigarettes per
day, and number of years of smoking.
4 Adjusted for age, socioeconomic status, prostate cancer in the family, and alcohol intake.
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sensitive to carcinogenesis. In rodents, no tumors were observed
in the kidney upon acrylamide administration (7–10). However,
the results of extrapolating the high acrylamide dosages that were
administered to animals to the low dosages that humans are
exposed to through food are uncertain. The activity or capacity of
enzymes in the metabolism of acrylamide may be either in-
creased or decreased at low doses, and humans may differ from
animals in their ability to otherwise detoxify or eliminate acryl-
amide or glycidamide.
The genotoxic action of glycidamide (35, 41, 42) is currently
adopted as the mechanism of carcinogenic action in acrylamide
cancer risk assessments. In a previous study, we observed posi-
tive associations between acrylamide intake and both endome-
trial and ovarian cancer risk (22), which might indicate that
disturbance of hormonal balances may also be a mechanism of
acrylamide carcinogenesis. Rodents may not be a good (quanti-
tative) model for such hormonal effects.
The associations between acrylamide intake and renal cell,
bladder, and prostate cancer risk that were observed in this study
may be a reflection of the potential hormonal influences of acryl-
amide. A recent in vitro study of glycidamide-induced gene ex-
pression in human breast and colon cancer cells adds to this
theory by showing up-regulation of genes that catalyze the con-
version of inactive androgen and estrogen precursors to active
forms, such as testosterone and 17-estradiol (43). Renal cell
cancer risk has been positively associated with estrogens in both
animals and humans (44, 45). In prospective cohort studies, in-
dications were found for an inverse association between estrogen
and bladder cancer risk, in the form of inverse associations be-
tween age at menopause and bladder cancer risk and between
lifetime years of ovulation and bladder cancer risk (46). In ad-
dition, both rodent and human bladder cells express estrogen
receptors, and estrogens inhibit bladder carcinogenesis in ro-
dents (46). If acrylamide were to increase the concentrations of
free estrogen in the body, that could explain both its positive
association with endometrial, ovarian cancer, and renal cell can-
cer risk and its negative association with bladder cancer risk in
females. Furthermore, acrylamide has been shown to decrease
concentrations of plasma testosterone in rats upon acrylamide
injection into the rat brain (47). This finding may explain the
decrease in HRs for prostate cancer in never smokers across the
quintiles of acrylamide intake that was observed in the present
study; the question of whether a high concentration of testoster-
one is indeed a risk factor for prostate cancer is, however, still
under debate (48). In a prospective cohort study, in which the risk
ratios for several hormones were mutually adjusted for each other
and for sex hormone–binding globulin, testosterone was posi-
tively associated and estrogens were negatively associated with
the risk of prostate cancer (49).
This study has some limitations. FFQs have limitations, as
discussed elsewhere (50), but they are the only feasible way to
assess dietary intake over a long period in large-scale epidemi-
ologic studies. Acrylamide adducts to hemoglobin can be used as
a biomarker of exposure (31), but they represent the exposure
during the preceding 3 mo only. Furthermore, biomarkers are not
specific with regard to the source of acrylamide. Thus, in bio-
marker studies of dietary acrylamide exposure, strict control for
smoking and passive smoking is of the utmost importance.
Moreover, the costs of using biomarkers limit the size of the
population that can be used in a study. The NLCS FFQ has
proved to be both valid (27) and reproducible (28) with respect to
TABLE 6
Acrylamide hazard ratios (HRs) (and 95% CIs) of renal cell cancer risk by
strata of several covariables and tests for interaction: the Netherlands
Cohort Study on diet and cancer (NLCS), 1986–19991
Interaction variable
HRs per 10-g/d
increment of acrylamide
P for
interaction
Smoking status
Never (n 93) 1.09 (0.89, 1.34) 0.83
Former (n 136) 1.13 (0.99, 1.30)
Current (n 110) 1.08 (0.92, 1.27)
Smoking (cigarettes/d) 0.83
0 (n 93) 1.09 (0.89, 1.34)
0 to15 (n 100) 1.11 (0.95, 1.31)
15 (n 146) 1.13 (0.99, 1.29)
Smoking duration (y) 0.28
0 (n 93) 1.09 (0.89, 1.34)
0 to30 (n 87) 0.98 (0.82, 1.16)
30 (n 159) 1.21 (1.07, 1.37)
Obesity (BMI; in kg/m2) 0.222
	30
All (n 322) 1.11 (1.01, 1.22)
Never smokers (n 84) 1.08 (0.87, 1.34)
30
All (n 17) 0.90 (0.57, 1.43)
Never smokers (n 9) —3
BMI (kg/m2)
20
All (n 6) —
Never smokers (n 1) —
20–25
All (n 161) 1.13 (1.01, 1.27)
Never smokers (n 36) 0.98 (0.76, 1.27)
25
All (n 172) 1.06 (0.92, 1.23)
Never smokers (n 56) 1.18 (0.88, 1.60)
Diabetes 0.432
No
All (n 322) 1.11 (1.01, 1.22)
Never smokers (n 88) 1.11 (0.90, 1.37)
Yes
All (n 17) 0.92 (0.61, 1.41)
Never smokers (n 5) —
Physical activity (min/d) 0.812
0.544
30
All (n 70) 1.09 (0.91, 1.28)
Never smokers (n 13) 1.23 (0.80, 1.89)
30–60
All (n 98) 1.09 (0.92, 1.30)
Never smokers (n 36) 0.93 (0.69, 1.25)
60–90
All (n 65) 1.15 (0.92, 1.42)
Never smokers (n 24) 0.96 (0.68, 1.36)
90
All (n 103) 1.12 (0.93, 1.36)
Never smokers (n 18) 1.39 (0.84, 2.30)
Alcohol intake (g/d) 0.522
0.844
0
All (n 83) 1.11 (0.93, 1.34)
Never smokers (n 39) 1.13 (0.81, 1.58)
0–5
All (n 82) 1.04 (0.85, 1.27)
Never smokers (n 28) 0.98 (0.69, 1.38)
5
All (n 159) 1.15 (1.01, 1.31)
Never smokers (n 19) 1.22 (0.85, 1.75)
1 HRs were calculated by using Cox proportional hazards analysis. Ad-
justed for age, sex, hypertension (yes or no), BMI, energy intake, fruit consump-
tion, vegetable consumption, and (where appropriate) smoking status (current or
not current), number of cigarettes/d, and number of years of smoking.
2 P value for all subjects.
3 An insufficient number of cases (all such).
4 P value for never smokers only.
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TABLE 7
Acrylamide hazard ratios (HRs) (and 95% CIs) of bladder cancer risk by
strata of several covariables and tests for interaction: the Netherlands
Cohort Study on diet and cancer (NCLS), 1986–19991
Interaction variable
HRs per 10-g/d
increment of acrylamide
P for
interaction
Smoking status 0.19
Never (n 155) 0.90 (0.77, 1.05)
Former (n 530) 1.06 (0.97, 1.15)
Current (n 525) 0.98 (0.89, 1.09)
Smoking (cigarettes/d) 0.02
0 (n 155) 0.90 (0.70, 1.05)
0 to15 (n 384) 0.93 (0.84, 1.02)
15 (n 671) 1.09 (1.00, 1.19)
Smoking duration (y) 0.23
0 (n 155) 0.90 (0.77, 1.05)
0 to30 (n 246) 0.99 (0.88, 1.10)
30 (n 809) 1.04 (0.96, 1.12)
Obesity (BMI; in kg/m2) 0.992
0.563
	30
All (n 1130) 1.01 (0.95, 1.07)
Never smokers (n 137) 0.93 (0.78, 1.10)
30
All (n 56) 1.00 (0.73, 1.37)
Never smokers (n 12) 0.79 (0.45, 1.40)
BMI (kg/m2) 0.402
20
All (n 22) 1.14 (0.69, 1.86)
Never smokers (n 3) —4
20–25
All (n 633) 0.98 (0.90, 1.06)
Never smokers (n 71) 0.85 (0.66, 1.09)
25
All (n 531) 1.04 (0.95, 1.14)
Never smokers (n 75) 1.00 (0.80, 1.25)
Diabetes 0.182
No
All (n 1163) 1.01 (0.95, 1.08)
Never smokers (n 148) 0.90 (0.77, 1.06)
Yes
All (n 47) 0.72 (0.46, 1.10)
Never smokers (n 7) —
Physical activity (min/d) 0.872
0.113
30
All (n 244) 0.95 (0.84, 1.08)
Never smokers (n 45) 0.86 (0.68, 1.07)
30–60
All (n 356) 1.01 (0.90, 1.14)
Never smokers (n 43) 0.64 (0.43, 0.96)
60–90
All (n 229) 1.00 (0.86, 1.16)
Never smokers (n 28) 1.28 (0.87, 1.91)
90
All (n 376) 1.03 (0.92, 1.14)
Never smokers (n 37) 0.99 (0.70, 1.41)
Alcohol intake (g/d) 0.672
0.563
0
All (n 146) 1.06 (0.92, 1.23)
Never smokers (n 39) 0.73 (0.51, 1.02)
0–5
All (n 265) 0.98 (0.87, 1.11)
Never smokers (n 62) 0.97 (0.73, 1.30)
5
All (n 783) 0.99 (0.91, 1.07)
Never smokers (n 48) 0.93 (0.70, 1.23)
1 HRs were calculated by using Cox proportional hazards analysis. Ad-
justed for age, sex, vegetable consumption, fruit consumption, tea consumption,
familyhistoryofbladdercancer,and(whereappropriate)smokingstatus(current
or not current), number of cigarettes/d, and number of years of smoking.
2 P values for all subjects.
3 P values for never smokers only.
4 An insufficient number of cases (all such).
TABLE 8
Acrylamide hazard ratios (HRs) (and 95% CIs) of prostate cancer risk by
strata of several covariables and tests for interaction: the Netherlands
Cohort Study on diet and cancer (NCLS), 1986–19991
Interaction variable
HRs per 10-g/d
increment of acrylamide
P for
interaction
Smoking status 0.26
Never (n 347) 0.95 (0.82, 1.09)
Former (n 1204) 1.06 (0.99, 1.14)
Current (n 695) 0.96 (0.87, 1.06)
Smoking (cigarettes/d) 0.39
0 (n 347) 0.95 (0.82, 1.09)
0 to15 (n 804) 1.05 (0.97, 1.13)
15 (n 1095) 1.00 (0.92, 1.09)
Smoking duration (y) 0.48
0 (n 347) 0.95 (0.82, 1.09)
0 to30 (n 642) 1.06 (0.96, 1.16)
30 (n 1257) 1.01 (0.94, 1.08)
Obesity 0.522
No
All (n 2122) 1.02 (0.96, 1.07)
Never smokers (n 327) 0.97 (0.84, 1.13)
Yes
All (n 67) 1.13 (0.78, 1.63)
Never smokers (n 9) —3
BMI (kg/m2) 0.442
20
All (n 34) 2.64 (1.28, 5.47)
Never smokers (n 9) —
20–25
All (n 1123) 1.03 (0.96, 1.11)
Never smokers (n 179) 1.06 (0.85, 1.31)
25
All (n 1032) 1.00 (0.93, 1.08)
Never smokers (n 148) 0.85 (0.68, 1.08)
Diabetes 0.992
0.124
No
All (n 2175) 1.02 (0.96, 1.07)
Never smokers (n 335) 0.94 (0.82, 1.08)
Yes
All (n 71) 0.88 (0.58, 1.34)
Never smokers (n 12) 1.97 (0.72, 5.35)
Physical activity (min/d) 0.202
0.094
30
All (n 351) 0.92 (0.82, 1.03)
Never smokers (n 54) 0.73 (0.51, 1.05)
30–60
All (n 673) 1.03 (0.93, 1.14)
Never smokers (n 91) 0.77 (0.59, 1.00)
60–90
All (n 502) 0.96 (0.84, 1.10)
Never smokers (n 85) 0.97 (0.68, 1.40)
90
All (n 698) 1.09 (0.99, 1.20)
Never smokers (n 114) 1.26 (0.94, 1.69)
Alcohol intake (g/d) 0.212
0.494
0
All (n 310) 0.99 (0.88, 1.12)
Never smokers (n 97) 0.94 (0.73, 1.20)
0–5
All (n 488) 1.12 (1.01, 1.24)
Never smokers (n 104) 1.17 (0.89, 1.54)
5
All (n 1448) 0.99 (0.92, 1.16)
Never smokers (n 146) 0.88 (0.70, 1.10)
1 HRs were calculated by using Cox proportional hazards analysis. Ad-
justed for age, socioeconomic status, family history of prostate cancer, alcohol
intake, and (where appropriate) smoking status (current or not current), number
of cigarettes/d, and number of years of smoking.
2 P value for all subjects.
3 An insufficient number of cases (all such).
4 P value for never smokers only.
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nutrients that correlate with acrylamide, such as carbohy-
drates and fiber. The acrylamide intake assessment is an im-
portant asset of the present study, as are its large study size and
prospective nature, the latter of which excludes selection and
recall bias. We used acrylamide concentrations in foods from
the Dutch market only, and we specifically sampled and an-
alyzed foods that were relevant for the NLCS population.
Within the validation study that we described in the Methods
section, visual inspection of the scatter plot and the Bland-
Altman plot showed that most of the estimated amounts were
higher than the corresponding measured amounts. This finding
implies that the use of mean values of acrylamide concentrations
in foods to estimate dietary acrylamide intake on a continuous
scale probably leads to some underestimation of the true
acrylamide-associated risk.
It has to be borne in mind that the variation in acrylamide
intake in our study was to a large extent due to Dutch spiced cake,
which resembles gingerbread of the cake-like, noncrusty type.
Dutch spiced cake does not necessarily contain ginger, but it
contains other spices and sometimes fruit. Concentrations of
acrylamide in Dutch spiced cake (mean: 1018 ppb) are much
higher than those in plain cake (mean:30 ppb). Because of the
addition of glucose and fructose syrup, Dutch spiced cake con-
tains a greater amount of reducing sugars than do other cakes. In
the presence of ammonium hydrogen carbonate, which is often
used as a baking agent in spiced cake, the formation of acryl-
amide is further enhanced (51). There is no indication that the
associations between acrylamide intake and renal cell, bladder,
and prostate cancer risk should be attributed to other ingredients
of spiced cake; the results did not change signficantly after ad-
justment for spiced cake.
For the interaction analyses, we calculated many HRs in many
small subgroups, which makes it likely that some of the observed
significant P values for interaction or HRs in subgroups were
spurious. Therefore, they should be interpreted cautiously, and
their analysis should be repeated in other epidemiologic studies.
Current populations, especially young people, consume larger
amounts of potato chips and French fries than did the NLCS
population. Because of the high acrylamide concentrations of
these foods, current dietary intake of acrylamide is assumed to be
considerably higher (29, 31, 52) than the intake in the present
study. In contrast, industry and science are investigating ways to
reduce acrylamide concentrations in food and have succeeded to
some extent with respect to certain foods (53).
Although replication in other prospective studies is needed,
the present study suggests that acrylamide is not neutral with
regard to carcinogenesis. Depending on the tissue, acrylamide
may have both carcinogenic and anticarcinogenic properties,
which suggests that the genotoxic action of glycidamide, the
epoxide metabolite of acrylamide, may not be the (only) pathway
through which acrylamide exerts its effects. The results of the
interaction analyses between acrylamide and the CYP2E1-
modifying variables also do not clearly point toward a
glycidamide-mediated genotoxic effect, because they do not
modify, or at least do not consistently modify, the association
between acrylamide intake and renal cell, bladder, and prostate
cancer risk.
We encourage other researchers to prospectively investigate
the association between dietary acrylamide intake and renal,
bladder, and prostate cancer risk; to perform subgroup analyses
for nonsmokers; and to study interactions with factors that mod-
ify CYP2E1 activity. In the mean time, the indications of a
positive association between acrylamide intake and endometrial,
ovarian, and renal cell cancer risk should be an incentive for food
industries to continue striving to lower acrylamide concentra-
tions in foods.
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